US Pharma MarketingAutoimmune disease company Oblenio Bio clinches $62M led by Pfizer Ventures
Oblenio Bio raises $62M Series B led by Pfizer Venture Investments to advance LBL-051, a trispecific TCE targeting BCMA, CD19, and CD3, into first-in-human trials for autoimmune disease. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act…
Oblenio Bio has secured $62 million in a Series B raise led by Pfizer Ventures to advance a trispecific T-cell engager (TCE) for autoimmune diseases into a first-in-human study.
The oversubscribed fundraise marks yet another ...
Source: Endpoints News